Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Medicines Company Aims For Mid-2008 Cleviprex Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

The third-generation, acute care calcium channel blocker’s FDA user fee date is in May 2008, COO Kelley tells “The Pink Sheet” DAILY.

You may also be interested in...



Can The Medicines Company Rebound From A Phase III Blow?

Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.

Can The Medicines Company Rebound From A Phase III Blow?

Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.

Can The Medicines Company Rebound From A Phase III Blow?

The Medicines Company will focus development of its reversible antithrombotic cangrelor on use as a "bridging" drug for patients who must break from Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) while undergoing surgery, after halting two Phase III trials in angioplasty patients because it was not showing approvable efficacy

Related Content

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel